Search the Newsreel

Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts

Castle Biosciences, Inc. (NASDAQ:CSTL) has received an average "Moderate Buy" recommendation from analysts, with a 12-month target price of $42.43. While the company met EPS expectations at -$0.49 and exceeded revenue estimates with $84.23 million, it remains unprofitable. Insider activity shows recent sales of …

Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Castle Biosciences Inc's (CSTL) financial health, noting its current score of 7.55 and ranking within the Healthcare Equipment & Supplies industry. It highlights the company's robust financial status but average operating efficiency. The report also details recent quarterly …

Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Castle Biosciences Inc (CSTL). It indicates that detailed data for business segments, regional revenue, and profit contribution for various fiscal years are not yet disclosed by the company. The only specific financial detail available is …

Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk

Castle Biosciences Inc (CSTL) has a current risk assessment score of 7.04, placing it 44th out of 200 in the Healthcare Equipment & Supplies industry. The company's beta of 1.07 indicates higher volatility compared to the S&P 500. The article details various risk metrics …

Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Castle Biosciences Inc (CSTL), listing major institutional holders and their respective proportions. It also presents a breakdown of shareholder types by category, showcasing the significant influence of investment advisors and hedge funds. Furthermore, the report includes institutional …

Castle Biosciences (CSTL) Expected to Post Quarterly Earnings on Thursday

Castle Biosciences (CSTL) is scheduled to release its Q2 2026 earnings on Thursday, July 30th, with analysts forecasting a loss of $0.44 per share on $86.24 million in revenue. The company's previous quarter exceeded revenue expectations, reporting $84.23 million against estimates of $79.23 million. …

Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference

Castle Biosciences, Inc. (Nasdaq: CSTL) will present a company overview at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 11:30 a.m. Eastern time. A live audio webcast will be available on the Company's investor relations website, with a replay accessible …

Castle Biosciences sets live webcast for Aug. 12 conference

Castle Biosciences (Nasdaq: CSTL) announced that its executive management will present a company overview at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 11:30 a.m. Eastern time. A live audio webcast and replay will be available on the company's …

New York State Department of Health Approves Castle’s AdvanceAD-Tx Test

The New York State Department of Health has approved Castle Biosciences, Inc.'s AdvanceAD-Tx test, a non-invasive gene expression profile test for guiding systemic therapy selection in moderate-to-severe atopic dermatitis patients. This approval broadens access to the test in New York, which helps clinicians personalize …

Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts

Castle Biosciences Inc. President and CEO Derek J. Maetzold reported selling 4,172 shares of common stock at a weighted-average price of $22.92 per share on July 14, 2026. These sales were largely executed through family trusts under a pre-arranged Rule 10b5-1 trading plan adopted …

Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com

Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down

How The Castle Biosciences (CSTL) Story Is Shifting After Solid Q1 And Lower Targets

Castle Biosciences Reports First Quarter 2026 Results

Castle Biosciences, Inc. Q1 2026 Earnings Call Summary

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates

Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern